CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
Prazosindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01178138
NCT01178138Phase 2Completed
CompareCT.gov

Monoamine Antagonist Therapies for Methamphetamine Abuse Prazosin

University of Arkansas·interventional·Posted Aug 9, 2010·Updated Dec 30, 2016

In Brief

A Phase 2 clinical trial evaluating Prazosin for Continuous Methamphetamine Abuse. Completed, enrolled 24 participants across 1 site.

Detailed Summary

This protocol will test the safety, effectiveness and the metabolism and action of prazosin as a potential therapy for methamphetamine abuse. This will be accomplished by performing a series of human laboratory studies. In each of these studies, the safety and effectiveness of the test medication (prazosin) in the treatment of methamphetamine effects will be determined. The study hypothesis is that prazosin will block the methamphetamine receptor function, reducing the reinforcing effects of central nervous system effects in humans.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsContinuous Methamphetamine Abuse
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 9, 2010
Enrollment StartDec 1, 2009
Primary CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 15.9 years ago

Interventions

Prazosindrug

Prazosin or oral placebo given before methamphetamine or iv placebo to determine effects of prazosin on methamphetamine.